Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 3
2006 1
2007 1
2008 2
2009 8
2011 2
2012 2
2013 3
2014 3
2015 2
2016 1
2017 2
2019 9
2020 6
2021 5
2022 5
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Results by year

Filters applied: . Clear all
Page 1
Corrigendum to "Clinical characteristics, impairment, and psychiatric morbidity in 102 youth with misophonia" [J. Affect. Disord. volume 324 (2023) 395-402].
Guzick AG, Cervin M, Smith EEA, Clinger J, Draper I, Goodman WK, Lijffijt M, Murphy N, Lewin AB, Schneider SC, Storch EA. Guzick AG, et al. Among authors: lijffijt m. J Affect Disord. 2024 Mar 1;348:410. doi: 10.1016/j.jad.2023.11.045. Epub 2023 Nov 30. J Affect Disord. 2024. PMID: 38040623 No abstract available.
Correction: Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.
Murphy N, Tamman AJF, Lijffijt M, Amarneh D, Iqbal S, Swann A, Averill LA, O'Brien B, Mathew SJ. Murphy N, et al. Among authors: lijffijt m. Neuropsychopharmacology. 2023 Oct;48(11):1699. doi: 10.1038/s41386-023-01618-z. Neuropsychopharmacology. 2023. PMID: 37349477 Free PMC article. No abstract available.
Neural complexity EEG biomarkers of rapid and post-rapid ketamine effects in late-life treatment-resistant depression: a randomized control trial.
Murphy N, Tamman AJF, Lijffijt M, Amarneh D, Iqbal S, Swann A, Averill LA, O'Brien B, Mathew SJ. Murphy N, et al. Among authors: lijffijt m. Neuropsychopharmacology. 2023 Oct;48(11):1586-1593. doi: 10.1038/s41386-023-01586-4. Epub 2023 Apr 19. Neuropsychopharmacology. 2023. PMID: 37076582 Free PMC article. Clinical Trial.
Identification of an optimal dose of intravenous ketamine for late-life treatment-resistant depression: a Bayesian adaptive randomization trial.
Lijffijt M, Murphy N, Iqbal S, Green CE, Iqbal T, Chang LC, Haile CN, Hirsch LC, Ramakrishnan N, Fall DA, Swann AC, Al Jurdi RK, Mathew SJ. Lijffijt M, et al. Neuropsychopharmacology. 2022 Apr;47(5):1088-1095. doi: 10.1038/s41386-021-01242-9. Epub 2021 Nov 27. Neuropsychopharmacology. 2022. PMID: 34839364 Free PMC article. Clinical Trial.
Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial.
Ramakrishnan N, Lijffijt M, Green CE, Balderston NL, Murphy N, Grillon C, Iqbal T, Vo-Le B, O'Brien B, Murrough JW, Swann AC, Mathew SJ. Ramakrishnan N, et al. Among authors: lijffijt m. Depress Anxiety. 2021 Nov;38(11):1108-1119. doi: 10.1002/da.23194. Epub 2021 Jul 12. Depress Anxiety. 2021. PMID: 34254405 Free PMC article. Clinical Trial.
48 results